Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
Recruiting
Observational Study
Pseudomonas Infections
Pseudomonas Aeruginosa
Prognosis
Drug Resistance, Multiple, Bacterial
Antibacterial Agents
Beta-lactam Antibiotics
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- Centre Hospitalier Régional d'Orléans · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients aged 18 or over and requiring intravenous definite antimicrobial therapy for a DTR P. aeruginosa infection
Exclusion Criteria:
* Cystic fibrosis
* P. aeruginosa DTR colonization or P. aeruginosa DTR infection not requiring definitive intravenous antibiotic thera…
Contacts